DK 157782 BDK 157782 B
5 Den foreliggende opfindelse angår et farmaceutisk præparat med differentieret frigivelse indeholdende pinacidil (N"-cyano-N-4-pyridyl-N,-1,2,2-trimethylpropyl-guanidin), om ønsket sammen med en eller flere terapeutisk aktive bestanddele og/eller hjælpestoffer.The present invention relates to a differentiated release pharmaceutical composition containing pinacidil (N "-cyano-N-4-pyridyl-N, -1,2,2-trimethylpropyl-guanidine), if desired together with one or more therapeutically active ingredients and / or excipients.
10 Pinacidil, dets fremstilling og brug er beskrevet i dansk patent nr. 145.341.Pinacidil, its preparation and use is described in Danish Patent No. 145,341.
Pinacidil har hidtil primært været anvendt i form af tabletter, men da pinacidils opløselighed i høj grad er afhængig af surhedsgraden (opløseligheden er i de næsten 15 neutrale tarmvæsker kun ca. 1% af dets opløselighed i den sure mavesaft) er tidspunktet, hvor de højeste koncentrationer opnås, meget afhængig af tablettens gennemløbstid gennem mave-tarmkanalen med resulterende svingninger i blodtrykket, hvilket er uheldigt, samtidig med at der fore-20 kommer flere bivirkninger.Pinacidil has so far been used primarily in the form of tablets, but since the solubility of pinacidil is highly dependent on the acidity (the solubility in the nearly 15 neutral intestinal fluids is only about 1% of its solubility in the acidic gastric juice), the time when the highest concentrations are obtained, highly dependent on the tablet's passage time through the gastrointestinal tract, with resultant fluctuations in blood pressure, which is unfortunate, while there are several side effects.
I nævnte danske patent nr. 145.341 foreslås også indgivelse af de beskrevne stoffer i form af tabletter med forsinket afgivelse. Når pinacidil indgives i form af tabletter med forsinket afgivelse af matrix-typen, som fx 25 beskrevet i britisk patent nr. 1.137.156, eller i tabletter, som er overtrukket for at forsinke afgivelse af indholdsstofferne, viser der sig imidlertid efter indgift til humane forsøgspersoner en stor variation i den individuelle resorptionshastighed og deraf følgende variationer i kon-30 centrationen i blodet, hvilket gør brugen af pinacidil ret uforudsigelig og derfor mindre attraktiv.The Danish patent no. 145,341 also proposes the administration of the described substances in the form of delayed-release tablets. However, when pinacidil is administered in the form of delayed matrix type tablets, as described, for example, in British Patent No. 1,137,156, or in tablets coated to delay delivery of the ingredients, after administration to human subjects showed a large variation in the individual rate of resorption and consequent variations in blood concentration, making the use of pinacidil quite unpredictable and therefore less attractive.
Man har nu konstateret, at de fundne ulemper med de kendte indgivelsesformer for pinacidil kan undgås ved anvendelse af en blanding af mindst to slags pellets inde-35 holdende pinacidil som den aktive bestanddel, om ønsket 2It has now been found that the disadvantages found with the known forms of administration of pinacidil can be avoided by using a mixture of at least two kinds of pellets containing pinacidil as the active ingredient, if desired.
DK 157782 BDK 157782 B
sammen med andre terapeutisk aktive bestanddele og bærerstoffer og/eller hjælpestoffer, idet de anvendte typer af pellets adskiller sig fra hinanden ved at tillade en frigivelse af deres aktive indhold ved forskellige pH-værdier, 5 fx én del med hurtig frigivelse i maven og langsom frigivelse i tarmen, og én eller flere dele, der overhovedet ikke afgiver deres bestanddele i maven, men derimod tillader en moderat frigivelse i tarmen.together with other therapeutically active constituents and carriers and / or adjuvants, the types of pellets used differing by allowing a release of their active content at various pH values, e.g., one fast-release portion in the stomach and slow release in the intestine, and one or more parts that do not release their constituents at all in the stomach but allow a moderate release in the intestine.
Præparatet ifølge opfindelsen er ejendommeligt ved 10 det i den kendetegnende del af krav 1 angivne. Det er ifølge opfindelsen særlig fordelagtigt, at én slags pellets frigiver sit indhold ved en pH-værdi under 4, og de(n) anden/andre slags frigiver deres indhold ved et højere pH, fortrinsvis mellem 6 og 7,5. En yderligere fordel opnås, 15 når mikroindkapslingsmaterialet vælges på en sådan måde, at frigivelsen af de aktive komponenter kun kan foregå i den ønskede del af mave-tarmkanalen. Derved undgås, at en utilsigtet hurtigere passage af den øvre del af mave-tarmkana-len kan føre til en større afgivelse end planlagt af de 20 aktive komponenter i den senere del af tarmkanalen.The composition of the invention is peculiar to that of the characterizing part of claim 1. According to the invention, it is particularly advantageous that one kind of pellet releases its content at a pH below 4 and the other (s) release their content at a higher pH, preferably between 6 and 7.5. A further advantage is obtained when the microencapsulating material is selected in such a way that the release of the active components can take place only in the desired part of the gastrointestinal tract. This avoids that an unintentionally faster passage of the upper part of the gastrointestinal tract can lead to a greater release than planned by the 20 active components in the later part of the intestinal tract.
Indkapslingsmaterialet for førstnævnte slags pellets er således polymere stoffer, som syntetiseres udfra akryleller metakrylestre med et lavt indhold af kvaternære ammo- db niumgrupper (Eudragitw RL), om ønsket med tilsætning af 25 hydrofile filmdannere, såsom polyethylenglykoler eller hydroxypropylmethylcellulose - eller polymerer syntetiseret udfra dimethylaminometakrylat og andre neutrale metakryl-syreestre (Eudragit ® E).Thus, the encapsulating material for the first kind of pellets are polymeric substances which are synthesized from acrylic or methacrylic esters with a low content of quaternary ammonium groups (Eudragitw RL), if desired with the addition of 25 hydrophilic film formers such as polyethylene glycols or hydroxypropyl methyl cellulose or other neutral methacrylic acid esters (Eudragit ® E).
Eudragit ® RL og E opløses ikke, men er gennemtrænge-30 lige i tarmens neutrale miljø. Hvis en farmaceutisk dosisenhed indeholdende et præparat ifølge den foreliggende opfindelse derfor skulle passere for hurtigt gennem maven, fx hvis den indgives på tom mave, vil det kun give ringe stigning i den tilsigtede frigjorte mængde af den aktive 35 komponent i tarmen.Eudragit ® RL and E do not dissolve, but are permeable to the intestinal neutral environment. Therefore, if a pharmaceutical dosage unit containing a composition of the present invention should pass too quickly through the stomach, for example if it is administered on an empty stomach, it will give only slight increase in the intentionally released amount of the active component of the intestine.
Den anden slags pellets fremstilles ved mikroindkaps-ling af den aktive komponent med et polymert stof udvalgt blandt anioniske metakrylsyre-metakrylsyremethylesterpoly- 3The second kind of pellets is prepared by microencapsulating the active component with a polymeric substance selected from anionic methacrylic acid-methacrylic acid methyl ester polymer.
DK 157782 BDK 157782 B
merer, såsom Eudragit ® L (6,0) og Eudragit ® S (7,0). Til polymererne kan der sættes blødgøringsstoffer, såsom diethyl- eller dibutylftalater, fx acetyltributylftalater, citronsyreestre, fx acetyltributylcitrat (Citroflex ®A-4), 5 glycerolestre med fede syrer, fx glyceryltriacetat, stearinsyre og fede alkoholer, såsom cetanol og polyethylengly-coler, såsom macrogol. Polymeren skal efter erosion i tarmen frigive den aktive forbindelse. En foretrukken polymer er Eudragit ®S.such as Eudragit ® L (6.0) and Eudragit ® S (7.0). Softeners can be added to the polymers, such as diethyl or dibutyl phthalates, e.g., acetyl tributyl phthalates, citric acid esters, e.g., acetyl tributyl citrate (Citroflex ® A-4), macrogol. The polymer should release the active compound after erosion in the gut. A preferred polymer is Eudragit ® S.
10 De mikroindkapslede pellets kan fremstilles på føl gende vis.The microencapsulated pellets can be prepared as follows.
Først fremstilles pinacidilpellets ved at overtrække en bærer, fx sukker/stivelse nonpareil, med en suspension af pinacidil.First, pinacidil pellets are prepared by coating a carrier, e.g., sugar / starch nonpareil, with a suspension of pinacidil.
15 Til fremstilling af den førstnævnte slags pellets (initialdosen) overtrækkes en mængde af de ovennævnte pinacidilpellets som allerede beskrevet, fx med en alkoholisk opløsning af Eudragit ® RL, hvilket resulterer i et overtræk på 2-10%, fortrinsvis ca. 4%, af vægten af 20 pellets.To prepare the first kind of pellets (the initial dose), an amount of the above-mentioned pinacid pellets is already coated, for example, with an alcoholic solution of Eudragit ® RL, which results in a coating of 2-10%, preferably approx. 4%, of the weight of 20 pellets.
Til fremstilling af den anden slags pellets (depoteller gentagelsesdosen) overtrækkes en yderligere mængde af de nævnte pinacidilpellets med en yderligere mængde Eudragit® S som ovenfor beskrevet, hvilket giver et over-25 træk, som udgår 5-20%, fortrinsvis ca. 12%, af vægten af pellets.For the preparation of the second kind of pellets (depot repetition dose), an additional amount of said pinacid pellets is coated with an additional amount of Eudragit® S as described above to give a coating of 5-20%, preferably approx. 12%, by weight of pellets.
Om ønsket, kan man ved valg af passende overtræksmaterialer fremstille andre slags pellets, hvorfra frigivelsen af de aktive materialer forsinkes yderligere, men 30 almindeligvis er det tilstrækkeligt at anvende de allerede omtalte to typer pellets.If desired, other types of pellets may be prepared by selecting suitable coating materials from which the release of the active materials is further delayed, but it is generally sufficient to use the two types of pellets already mentioned.
De ovennævnte pellets indgår ifølge opfindelsen i dosisenheder til brug for en patient, som behøver behandling.The above pellets according to the invention are included in dosage units for use by a patient in need of treatment.
35 Ved betegnelsen "dosisenhed" forstås en enhedsdosis, dvs. en enkelt dosis, som kan indgives til en patient, og som let kan håndteres og pakkes, idet den forbliver en fysisk stabil enhedsdosis omfattende en blanding af de 4The term "dosage unit" means a unit dose, i.e. a single dose which can be administered to a patient and which can be easily handled and packaged, remaining a physically stable unit dose comprising a mixture of the 4
DK 157782 BDK 157782 B
ovennævnte slags pellets som sådanne, eller sammen med passende farmaceutisk acceptable, ugiftige bærere og/eller hjælpestoffer, fx i form af tabletter eller kapsler.the aforementioned kind of pellets as such, or together with suitable pharmaceutically acceptable non-toxic carriers and / or excipients, for example in the form of tablets or capsules.
Til fremstilling af de endelige dosisenheder blandes 5 passende mængder pellets, som udgør henholdsvis initialdosis og gentagelsesdosis, og som fortrinsvis fyldes i kapsler.To prepare the final dosage units, 5 appropriate amounts of pellets constituting the initial dose and repeat dose, respectively, and preferably filled into capsules are mixed.
Forholdet mellem initialdosen og gentagelsesdosen kan variere fra 1:10 til 10:1 med det foretrukne forhold på fra 10 ca. 1:5 til. 5:1, i særdeleshed mellem 1:4 og 1:1.The ratio of the initial dose to the repeat dose can range from 1:10 to 10: 1 with the preferred ratio of from about 10 to about 10: 1. 1: 5 to. 5: 1, in particular between 1: 4 and 1: 1.
Mængden af pellet-blandingen vælges med henblik på det ønskede indhold af pinacidil i de færdige præparater.The amount of the pellet mixture is selected for the desired content of pinacidil in the finished preparations.
fifi
Hver dosisenhed kan indeholde ca. 10 til 10 pellets.Each dosage unit may contain approx. 10 to 10 pellets.
Det foretrukne antal pellets er omkring 200 til 1000. Såle- 15 des skal hver pellet af præparatet indeholde en brøkdel af en terapeutisk effektiv dosis af den aktive bestanddel.The preferred number of pellets is about 200 to 1000. Thus, each pellet of the composition should contain a fraction of a therapeutically effective dose of the active ingredient.
“6 -"1“6 -” 1
Denne brøkdel kan være 1 * 10~ til 1 * 10~ gange en sådan -3 -3 dosis og fortrinsvis 1 * 10 til 5 * 10 gange sådan dosis. Blandt egnede dosisenheder kan især nævnes kapsler 20 og tabletter, hvoraf kapsler vil være den foretrukne udførelsesform. Farmaceutisk acceptable tilsætningsstoffer kan også indgå i de ifølge opfindelsen fremstillede dosisenheder. Præparater til suspendering før brug er ligeledes anvendelige.This fraction may be 1 * 10 ~ to 1 * 10 ~ times such a -3 -3 dose and preferably 1 * 10 to 5 * 10 times such dose. Particularly suitable dosage units include capsules 20 and tablets, capsules of which will be the preferred embodiment. Pharmaceutically acceptable additives may also be included in the dosage units of the invention. Preparations for suspending before use are also useful.
25 Som ovenfor nævnt kan de forskellige typer pellets blandes i varierende forhold, hvilket muliggør en ændring af det tidspunkt, hvor den antihypertensive virkning indsætter, og varigheden af denne.As mentioned above, the different types of pellets can be mixed in varying ratios, allowing a change in the duration and duration of the antihypertensive effect.
De foreliggende farmaceutiske præparater er fordel-30 agtige ved, at de muliggør en behandling med mindre hyppig indgift. Med de hidtil anvendte traditionelle tabletter var det nødvendigt med mindst 4 gange daglig indgift, selv ved brug af-præparater med langsom afgivelse af normal type.The present pharmaceutical compositions are advantageous in that they enable a treatment with less frequent administration. With the traditional tablets used so far, at least 4 times daily administration was required, even when using normal-type slow-release preparations.
Med de foreliggende præparater er det muligt at følge 35 en kur med indgift tre gange daglig, samt i nogle tilfælde endog kun to gange. Da ikke-overholdelse er en almindelig årsag t'i'l tilsyneladende svigt i behandling med antihyper-tensiv medicin, udgør de foreligende præparater et virke- 5With the present compositions, it is possible to follow a regimen of administration three times daily, and in some cases even twice. Since non-compliance is a common cause of apparent failure in antihypertensive drug treatment, the present compositions constitute an effective agent.
DK 157782 BDK 157782 B
ligt fremskridt.equal progress.
Som ovenfor angivet kan de foreliggende præparater indeholde andre terapeutisk aktive bestanddele, som almindeligvis anvendes ved behandling af hypertension, såsom 5 diuretika og/eller β-blokkere, fx som beskrevet i det tidligere nævnte danske patent nr. 145.341.As stated above, the present compositions may contain other therapeutically active ingredients commonly used in the treatment of hypertension, such as diuretics and / or β-blockers, for example, as described in the aforementioned Danish Patent No. 145,341.
De foreliggende præparater har vist sig at besidde en god stabilitet under længere tids opbevaring.The present compositions have been found to have good stability during prolonged storage.
Præparaterne ifølge opfindelsen skal yderligere belt) skrives i følgende eksempel.The compositions of the invention are to be further belted in the following example.
Eksempel I. Fremstilling af Pinacidil-pelletsExample I. Preparation of Pinacidil Pellets
Pinacidil monohydrat 50 g 15 Polysorbat 80 0,5 gPinacidil monohydrate 50 g Polysorbate 80 0.5 g
Afjoniseret vand 100 mlDeionized water 100 ml
Silicone Antifoam M-30 emulsion 1,5 gSilicone Antifoam M-30 emulsion 1.5 g
Suspensionen findeltes i en 600 ml glasflaske i mindst to timer under anvendelse af glaskugler med en diameter på 20 6 mm. Partikelstørrelsen kontrolleredes ved mikroskopi, og formalingen fortsattes, indtil de fleste partikler havde en størrelse på under 30 μιη.The suspension was comminuted in a 600 ml glass bottle for at least two hours using glass beads 20 mm in diameter. The particle size was checked by microscopy and the grinding continued until most particles were less than 30 μιη.
Suspension og glaskugler adskiltes i en Buchner-tragt (uden brug af filtrerpapir). Kuglerne vaskedes med 50 ml 25 afjoniseret vand, og skyllevandet sattes til den fraskilte suspension, som derefter blandedes med 17 g af en 6 centi-poise opløsning af hydroxypropylmethylcellulose i 170 ml af-joniseret vand. Den resulterende suspension indeholdt ca. 13^ pinacidilmonohydrat og h°/o hydroxypropylmethylcellulose.Suspension and glass beads were separated into a Buchner funnel (without the use of filter paper). The beads were washed with 50 ml of deionized water and the rinse water was added to the separated suspension, which was then mixed with 17 g of a 6 centipoise solution of hydroxypropyl methylcellulose in 170 ml of deionized water. The resulting suspension contained approx. 13 µm pinacidil monohydrate and h ° / o hydroxypropyl methyl cellulose.
30 333 g sukker/stivelses-non-pareils blev overtrukket med den således fremstillede suspension, under anvendelse af en fluid-bed forstøvningsgranulator.30 333 g of sugar / starch non-pareils were coated with the suspension thus prepared, using a fluid-bed nebulizer granulator.
DK 157782 BDK 157782 B
66
II. Overtrækning af initialdosen med, Eudragit ® RLII. Coating the initial dose with, Eudragit ® RL
ffisffis
Eudragit ^ RL 16 g opløstes iEudragit ^ RL 16 g was dissolved in
Ethanol 99,9°/> 250 ml 5 Afjoniseret vand 15 mlEthanol 99.9 ° /> 250 ml 5 Deionized water 15 ml
Diethylftalat 1,6 g 4 g Talkum suspenderedes i forstøvningsvæsken, som under stadig omrøring påførtes 400 g pinacidil-pellets i en fluid-bed forstøvningsgranulator.Diethyl phthalate 1.6 g of 4 g of talc was suspended in the nebuliser, which, while still stirring, applied 400 g of pinacidil pellets in a fluid-bed nebulizer.
10 Om ønsket, kunne Eudragit ® RL erstattes af Eudra git ®E eller Eudragit ® E30D.10 If desired, Eudragit ® RL could be replaced by Eudra git ® E or Eudragit ® E30D.
ffisffis
III. Overtrækning af gentagelsesdosen med Eudragit ^ SIII. Coating the repeat dose with Eudragit ^ S
Eudragit ® S 50 g 15 opløstes iEudragit ® S 50 g 15 was dissolved in
Ethanol 99>9$ 800 mlEthanol 99> 9 $ 800 ml
Afjoniseret vand 40 mlDeionized water 40 ml
Diethylftalat 5 g 12,5 S Talkum suspenderedes i forstøvningsvæsken under 20 stadig omrøring og påførtes 400 g pinacidilpellets i en fluid-bed forstøvningsgranulator.Diethyl phthalate 5 g 12.5 S Talc was suspended in the nebulizer liquid while still stirring and applied 400 g pinacid pellets in a fluid-bed nebulizer granulator.
IV. Blanding af initialdosen og gentagelsesdosen 421,6 g Pinacidil-pellets, overtrukket som beskrevet 25 under II ovenfor, blandedes med 467,5 g pinacidil-pellets, overtrukket som beskrevet under III ovenfor, i 15 minutter i en kubisk blandemaskine efter en let påføring af magnesium s tear at- støv.IV. Mixing the initial dose and repeat dose 421.6 g Pinacidil pellets coated as described under II above were mixed with 467.5 g pinacidil pellets coated as described under III above for 15 minutes in a cubic mixer after lightly applying magnesium s tear at- dust.
Hvis således pinacidilindholdet i pellets var højere 30 end 11^, kunne en kapsel af størrelse 2 indeholde en dosis svarende til 25 mg pinacidilmonohydrat. Hvis pellets pina-cidilindhold var højere end 8°/0f kunne en kapsel af størrelse 4 indeholde en dosis svarende til 10 mg pinacidilmonohydrat.Thus, if the pinacidil content of pellets was higher than 11 1, a size 2 capsule could contain a dose equivalent to 25 mg of pinacidil monohydrate. If the pina- cidil content of the pellet was higher than 8 ° / 0f, a size 4 capsule could contain a dose equal to 10 mg of pinacidil monohydrate.
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK56484ADK157782C (en) | 1983-02-11 | 1984-02-09 | PHARMACEUTICAL PREPARATION WITH DIFFERENTIATED DELIVERY AND CONTAINING PINACIDIL AS ACTIVE INGREDIENT |
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK0589/83ADK58983D0 (en) | 1983-02-11 | 1983-02-11 | PHARMACEUTICAL PREPARATION |
| DK58983 | 1983-02-11 | ||
| DK56484 | 1984-02-09 | ||
| DK56484ADK157782C (en) | 1983-02-11 | 1984-02-09 | PHARMACEUTICAL PREPARATION WITH DIFFERENTIATED DELIVERY AND CONTAINING PINACIDIL AS ACTIVE INGREDIENT |
| Publication Number | Publication Date |
|---|---|
| DK56484D0 DK56484D0 (en) | 1984-02-09 |
| DK56484A DK56484A (en) | 1984-08-12 |
| DK157782Btrue DK157782B (en) | 1990-02-19 |
| DK157782C DK157782C (en) | 1990-08-13 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK56484ADK157782C (en) | 1983-02-11 | 1984-02-09 | PHARMACEUTICAL PREPARATION WITH DIFFERENTIATED DELIVERY AND CONTAINING PINACIDIL AS ACTIVE INGREDIENT |
| Country | Link |
|---|---|
| DK (1) | DK157782C (en) |
| Publication number | Publication date |
|---|---|
| DK56484A (en) | 1984-08-12 |
| DK157782C (en) | 1990-08-13 |
| DK56484D0 (en) | 1984-02-09 |
| Publication | Publication Date | Title |
|---|---|---|
| US6663888B2 (en) | Pulsatile release histamine H2 antagonist dosage form | |
| JP5705319B2 (en) | Gastric juice-resistant pharmaceutical or nutritional supplement containing one or more alginic acid salts | |
| FI90393B (en) | Process for the preparation of an oral pharmaceutical formulation which is stable against discoloration | |
| RU2240110C2 (en) | New preparation | |
| JP6161701B2 (en) | Pharmaceutical or nutraceutical composition having sustained release characteristics and resistance to the effects of ethanol | |
| KR101141508B1 (en) | Pantoprazole multiparticulate formulations | |
| NO175286B (en) | A process for the preparation of a pharmaceutical composition comprising double-walled microcapsules | |
| CZ296964B6 (en) | Tramadol multiple unit pharmaceutical formulations and process of their preparation | |
| BG65398B1 (en) | EXTERNALLY COVERED PHARMACEUTICAL COMPOSITION AND METHOD FOR RECEIPT | |
| JP6474421B2 (en) | Pharmaceutical composition or nutritional functional food composition having sustained release characteristics and resistance to the effects of ethanol | |
| JP6695337B2 (en) | Pharmaceutical composition or nutraceutical composition having resistance to the influence of ethanol | |
| DK171155B1 (en) | Slow release diltiazem preparation | |
| KR20180015245A (en) | Pharmaceutical or nutraceutical composition with resistance against the influence of ethanol | |
| US4600577A (en) | Pharmaceutical preparations of pinacidal | |
| US20050025824A1 (en) | Pulsatile release histamine H2 antagonist dosage form | |
| KR20110102339A (en) | Tamsulosin pellets for fixed dose combinations | |
| EP1128826B1 (en) | Chromone enteric release formulation | |
| DK158599B (en) | Allergen preparation for oral administration | |
| WO2005053659A1 (en) | An improved pharmaceutical formulation containing tamsulosin salt and a process for its preparation | |
| EP1935422A1 (en) | Pharmaceutical composition comprising nicotinamide or nicotinic acid | |
| DK157782B (en) | PHARMACEUTICAL PREPARATION WITH DIFFERENTIATED DELIVERY AND CONTAINING PINACIDIL AS ACTIVE INGREDIENT | |
| WO2010036975A2 (en) | Dipyridamole and acetylsalicylic acid formulations and process for preparing same | |
| JPH0440327B2 (en) |